AZN:NYE-Astrazeneca PLC

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 36.55

Change

0.00 (0.00)%

Market Cap

USD 92.62B

Volume

4.37M

Average Target Price

USD 45.60 (24.76%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-19 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

N/A

USD 350.51B
PFE Pfizer Inc.

N/A

USD 245.84B
NVS Novartis AG

N/A

USD 205.57B
MRK Merck & Company Inc. (new)

N/A

USD 197.29B
ABBV AbbVie Inc.

N/A

USD 134.63B
LLY Eli Lilly and Company

N/A

USD 123.51B
GSK GlaxoSmithKline PLC

N/A

USD 96.96B
BMY Bristol-Myers Squibb Company

N/A

USD 81.82B
TAK Takeda Pharmaceutical Company ..

N/A

USD 61.38B
AGN Allergan plc

N/A

USD 54.04B

ETFs Containing AZN

ADRU Invesco BLDRS Europe Sele.. 0.00 % 0.30 %

N/A

USD 0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.77% 8% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.77% 8% F 4% F
Trailing 12 Months  
Capital Gain 3.13% 79% C+ 85% B
Dividend Return 3.95% 83% B 64% D
Total Return 7.08% 74% C 85% B
Trailing 5 Years  
Capital Gain 14.70% 65% D 64% D
Dividend Return 21.72% 93% A 66% D
Total Return 36.42% 65% D 65% D
Average Annual (5 Year Horizon)  
Capital Gain 2.03% 58% F 55% F
Dividend Return 6.29% 63% D 56% F
Total Return 4.26% 93% A 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 14.46% 79% C+ 51% F
Risk Adjusted Return 43.52% 63% D 52% F
Market Capitalization 65.58B 73% C 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.84 58% F 34% F
Price/Book Ratio 2.73 44% F 27% F
Price / Cash Flow Ratio 1.99 72% C- 58% F
Price/Free Cash Flow Ratio 85.00 4% F 5% F
Management Effectiveness  
Return on Equity 16.48% 77% C+ 75% C
Return on Invested Capital 11.58% 54% F 62% D-
Return on Assets 3.91% 58% F 60% D-
Debt to Equity Ratio 114.25% 28% F 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.